2016 Form 10-K Financial Statement

#000114420417007088 Filed on February 09, 2017

View on sec.gov

Income Statement

Concept 2016 2015 Q4 2015
Revenue $12.03M $2.740M $7.300M
YoY Change 64.76% 94.33% 32.42%
Cost Of Revenue $7.113M $1.600M $3.951M
YoY Change 80.04% 142.42% 53.81%
Gross Profit $4.915M $1.140M $3.349M
YoY Change 46.74% 52.0% 13.75%
Gross Profit Margin 40.86% 41.61% 45.88%
Selling, General & Admin $15.73M $3.390M $12.73M
YoY Change 23.55% 44.26% 66.67%
% of Gross Profit 320.03% 297.37% 380.12%
Research & Development $4.394M $1.070M $3.895M
YoY Change 12.83% 33.75% -4.45%
% of Gross Profit 89.42% 93.86% 116.29%
Depreciation & Amortization $251.3K $60.00K $222.6K
YoY Change 12.91% 20.0% 53.41%
% of Gross Profit 5.11% 5.26% 6.65%
Operating Expenses $20.12M $4.460M $16.63M
YoY Change 21.04% 41.14% 41.92%
Operating Profit -$15.21M -$3.320M -$13.28M
YoY Change 14.55% 37.76% 51.38%
Interest Expense $290.0K $610.0K $4.090M
YoY Change -92.91% -222.0% 289.52%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0%
Pretax Income -$14.91M -$2.710M -$9.190M
YoY Change 62.24% -6.87% 18.28%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.91M -$2.710M -$9.187M
YoY Change 62.32% -6.87% 18.3%
Net Earnings / Revenue -123.99% -98.91% -125.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$248.5M -$67.75M -$306.3M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2016 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.950M $12.46M $12.46M
YoY Change -68.3% 35.14% 35.14%
Cash & Equivalents $3.950M $12.46M $12.46M
Short-Term Investments
Other Short-Term Assets $1.650M $850.0K $850.0K
YoY Change 94.12% 39.34% 39.34%
Inventory $1.250M $1.089M $1.090M
Prepaid Expenses
Receivables $740.0K $742.7K $810.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.590M $15.15M $15.21M
YoY Change -50.1% 36.58% 37.15%
LONG-TERM ASSETS
Property, Plant & Equipment $530.0K $683.5K $680.0K
YoY Change -22.06% 119.42% 119.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $160.0K $200.0K $200.0K
YoY Change -20.0%
Total Long-Term Assets $690.0K $887.2K $890.0K
YoY Change -22.47% 184.27% 187.1%
TOTAL ASSETS
Total Short-Term Assets $7.590M $15.15M $15.21M
Total Long-Term Assets $690.0K $887.2K $890.0K
Total Assets $8.280M $16.03M $16.10M
YoY Change -48.57% 40.63% 41.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $730.0K $1.060M $1.060M
YoY Change -31.13% 102.75% 103.85%
Accrued Expenses $1.960M $1.055M $1.900M
YoY Change 3.16% -16.55% -11.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.320M $3.257M $3.260M
YoY Change 1.84% 20.7% 20.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $280.0K $280.0K
YoY Change -100.0% -94.74% -94.74%
Total Long-Term Liabilities $0.00 $280.0K $280.0K
YoY Change -100.0% -94.74% -94.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.320M $3.257M $3.260M
Total Long-Term Liabilities $0.00 $280.0K $280.0K
Total Liabilities $3.320M $3.537M $3.540M
YoY Change -6.21% -55.87% -55.86%
SHAREHOLDERS EQUITY
Retained Earnings -$163.6M
YoY Change 5.95%
Common Stock $405.00
YoY Change 98.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.960M $12.56M $12.56M
YoY Change
Total Liabilities & Shareholders Equity $8.280M $16.10M $16.10M
YoY Change -48.57% 41.2% 41.23%

Cashflow Statement

Concept 2016 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$14.91M -$2.710M -$9.187M
YoY Change 62.32% -6.87% 18.3%
Depreciation, Depletion And Amortization $251.3K $60.00K $222.6K
YoY Change 12.91% 20.0% 53.41%
Cash From Operating Activities -$15.08M -$3.480M -$13.10M
YoY Change 15.11% 49.36% 70.57%
INVESTING ACTIVITIES
Capital Expenditures $100.5K $0.00 $594.6K
YoY Change -83.1% -100.0% 161.59%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K $0.00 -$590.0K
YoY Change -83.05% -100.0% 156.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.670M 6.830M 16.94M
YoY Change -60.63% 68200.0% 113.62%
NET CHANGE
Cash From Operating Activities -15.08M -3.480M -13.10M
Cash From Investing Activities -100.0K 0.000 -590.0K
Cash From Financing Activities 6.670M 6.830M 16.94M
Net Change In Cash -8.510M 3.350M 3.250M
YoY Change -361.85% -235.08% 16150.0%
FREE CASH FLOW
Cash From Operating Activities -$15.08M -$3.480M -$13.10M
Capital Expenditures $100.5K $0.00 $594.6K
Free Cash Flow -$15.18M -$3.480M -$13.69M
YoY Change 10.85% 60.37% 73.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13099853 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15080276 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
594606 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100499 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-594606 USD
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-275662 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-9187348 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-14913151 USD
CY2015Q4 nuro Common Stock Warrants
CommonStockWarrants
280303 USD
CY2015Q4 us-gaap Liabilities
Liabilities
3536893 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
669 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
405 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163565650 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
4960764 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
12562708 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8283891 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16099601 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3318486 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3256590 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 nuro Common Stock Warrants
CommonStockWarrants
4641 USD
CY2016Q4 us-gaap Liabilities
Liabilities
3323127 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
183438878 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
176127932 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178478801 USD
CY2014 us-gaap Revenues
Revenues
5512764 USD
CY2015 us-gaap Revenues
Revenues
7299830 USD
CY2016 us-gaap Revenues
Revenues
12027528 USD
CY2015 us-gaap Gross Profit
GrossProfit
3349084 USD
CY2014 us-gaap Gross Profit
GrossProfit
2944162 USD
CY2014 us-gaap Cost Of Revenue
CostOfRevenue
2568602 USD
CY2015 us-gaap Cost Of Revenue
CostOfRevenue
3950746 USD
CY2016 us-gaap Cost Of Revenue
CostOfRevenue
7113005 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-267583 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
57349 USD
CY2016 us-gaap Gross Profit
GrossProfit
4914523 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4075976 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3894786 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4394353 USD
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2913112 USD
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7232971 USD
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10855445 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4725123 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5497513 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4872670 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
11714211 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
16625270 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
20122468 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-8770049 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-13276186 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-15207945 USD
CY2014 us-gaap Interest And Other Income
InterestAndOtherIncome
4606 USD
CY2015 us-gaap Interest And Other Income
InterestAndOtherIncome
5232 USD
CY2016 us-gaap Interest And Other Income
InterestAndOtherIncome
19132 USD
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1050095 USD
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4083606 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-7766222 USD
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.15
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.75
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.28
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1743494 shares
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2719285 shares
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4777037 shares
CY2016 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2015 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0 USD
CY2014 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
50874 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289873 USD
CY2016 nuro Stock Issued During Period Value Public Offering
StockIssuedDuringPeriodValuePublicOffering
6738500 USD
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2014 nuro Stock Issued During Period Value To Settle Incentive Compensation Obligations
StockIssuedDuringPeriodValueToSettleIncentiveCompensationObligations
104405 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302415 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
225408 USD
CY2014 nuro Stock Issued During Period Value Public Offering
StockIssuedDuringPeriodValuePublicOffering
3539947 USD
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
37824 USD
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
24137 USD
CY2015 nuro Stock Issued During Period Value To Settle Incentive Compensation Obligations
StockIssuedDuringPeriodValueToSettleIncentiveCompensationObligations
281757 USD
CY2016 nuro Stock Issued During Period Value To Settle Incentive Compensation Obligations
StockIssuedDuringPeriodValueToSettleIncentiveCompensationObligations
318761 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
3387115 USD
CY2015 nuro Issuance Of Preferred Stock And Warrants Under Underwritten Public Offerieng Value
IssuanceOfPreferredStockAndWarrantsUnderUnderwrittenPublicOfferiengValue
13290379 USD
CY2015 nuro Stock Issued During Period Value Redemption Of Preferred Stock
StockIssuedDuringPeriodValueRedemptionOfPreferredStock
2262934 USD
CY2015 nuro Stock Issued During Period Values Preferred Stock And Warrants
StockIssuedDuringPeriodValuesPreferredStockAndWarrants
6713500 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
222592 USD
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
251327 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
302415 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
225408 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
225619 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-69096 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
409344 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
163154 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
447541 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
347176 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
192489 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
754797 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
478760 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
401064 USD
CY2015 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
-281757 USD
CY2016 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
-318761 USD
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6667038 USD
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
20141703 USD
CY2014 us-gaap Depreciation
Depreciation
145100 USD
CY2016Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100499 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3240887 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8513737 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9221985 USD
CY2016 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 USD
CY2015 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
3206357 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6667038 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16935346 USD
CY2016 nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
CY2015 nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
145100 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
289873 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
189318 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.02
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.72
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.85
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.95
CY2015Q4 nuro Technology Fees
TechnologyFees
450000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
382000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.24
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.67
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4857.94
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.57
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
487922 USD
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
782364 shares
CY2016Q4 nuro Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Price Per Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePricePerShares
4.57
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2016 us-gaap Depreciation
Depreciation
251327 USD
CY2015 us-gaap Depreciation
Depreciation
222592 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
336229 USD
CY2016Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
48140 USD
CY2015Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
56284 USD
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.07 pure
CY2016Q4 nuro Accrued Consulting Fees
AccruedConsultingFees
48000 USD
CY2015Q4 nuro Accrued Consulting Fees
AccruedConsultingFees
92000 USD
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
0 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.042 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.085 pure
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
232391 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
120970 USD
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.002 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.145 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.036 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.009 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.013 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.01 pure
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
116704 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
195454 USD
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
199975 USD
CY2014 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
998434 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-44956 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-227308 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26232 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9195753 USD
CY2014 nuro Stock Issuance Settle Incentive Compensation Obligation
StockIssuanceSettleIncentiveCompensationObligation
-104405 USD
CY2014 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7932033 USD
CY2014 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7932033 USD
CY2014 nuro Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
4418824 USD
CY2014 nuro Equity Offering Costs Included In Accounts Payable And Accrued Expenses
EquityOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0 USD
CY2016 nuro Equity Offering Costs Included In Accounts Payable And Accrued Expenses
EquityOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0 USD
CY2015 nuro Equity Offering Costs Included In Accounts Payable And Accrued Expenses
EquityOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
100000 USD
CY2016 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
6700000 USD
CY2016 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
7500000 USD
CY2016Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
45879 USD
CY2015Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
10484 USD
CY2016 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.12 pure
CY2015 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.19 pure
CY2014 nuro Sales Revenue Goods Net Percentage From Foreign Country
SalesRevenueGoodsNetPercentageFromForeignCountry
0.19 pure
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31815153 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5694372 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
963556 shares
CY2016 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
0 USD
CY2015 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
4140446 USD
CY2014 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Embedded Features
DeemedDividendsAttributableToPreferredStockInConnectionWithEmbeddedFeatures
2955668 USD
CY2016 nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
0 USD
CY2015 nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
589751 USD
CY2014 nuro Return Of Capital To Common Shareholders Attributable From Repurchase Of Preferred Shares And Related Embedded Beneficial Conversion Features
ReturnOfCapitalToCommonShareholdersAttributableFromRepurchaseOfPreferredSharesAndRelatedEmbeddedBeneficialConversionFeatures
0 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21070255 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10721890 USD
CY2016 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Preferred Stock Modification
DeemedDividendsAttributableToPreferredStockInConnectionWithPreferredStockModification
19846377 USD
CY2015 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Preferred Stock Modification
DeemedDividendsAttributableToPreferredStockInConnectionWithPreferredStockModification
8332212 USD
CY2014 nuro Deemed Dividends Attributable To Preferred Stock In Connection With Preferred Stock Modification
DeemedDividendsAttributableToPreferredStockInConnectionWithPreferredStockModification
0 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
500000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
214813 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
575500 shares
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7688 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
261 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
782364 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
679013 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.81
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
168229 shares
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.48
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2016 dei Entity Registrant Name
EntityRegistrantName
NeuroMetrix, Inc.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001289850
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
0 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements Other
EffectiveIncomeTaxRateReconciliationTaxSettlementsOther
0.109 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.393 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.583 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.347 pure
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45759780 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40397318 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2180700 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2005741 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
752866 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
704957 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
566487 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
538321 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
14321 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
13698 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49274154 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43660035 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49274154 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43660035 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 nuro Income Tax Expense Benefit Attributable To Net Operating Loss Carry Forward
IncomeTaxExpenseBenefitAttributableToNetOperatingLossCarryForward
3900000 USD
CY2016Q4 nuro Income Tax Expense Benefit Attributable To Tax Credit Carry Forwards
IncomeTaxExpenseBenefitAttributableToTaxCreditCarryForwards
71000 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
581928 USD
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
679026 USD
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
638679 USD
CY2016Q4 us-gaap Purchase Obligation
PurchaseObligation
1699823 USD
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
833831 USD
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
833831 USD
CY2016Q4 nuro Common Stock Warrants Fair Value Disclosure
CommonStockWarrantsFairValueDisclosure
4641 USD
CY2016Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
4641 USD
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1865498 USD
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
1865498 USD
CY2015Q4 nuro Common Stock Warrants Fair Value Disclosure
CommonStockWarrantsFairValueDisclosure
280303 USD
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
280303 USD
CY2016Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
2500000 USD
CY2016 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2018-01-15
CY2016Q4 nuro Restricted Cash Collateral Letters Of Credit
RestrictedCashCollateralLettersOfCredit
896571 USD
CY2016Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
1600000 USD
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29154716 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6694901 shares
CY2016 nuro Minimum Closing Bid Price In Market
MinimumClosingBidPriceInMarket
1.00
CY2016 nuro Minimum Bid Closing Price Of Ten Consecutive Business Days Per Shares
MinimumBidClosingPriceOfTenConsecutiveBusinessDaysPerShares
1.00
CY2016 nuro Common Stock Outstanding Immediately Prior To Reverse Stock Split
CommonStockOutstandingImmediatelyPriorToReverseStockSplit
13785239 shares
CY2016 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
3446274 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q2 dei Entity Public Float
EntityPublicFloat
7760679 USD
CY2016 dei Trading Symbol
TradingSymbol
NURO
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7914901 shares
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
628236 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
227172 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
19846377 USD
CY2015 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
11882907 USD
CY2014 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2955668 USD
CY2016 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34759528 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21070255 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10721890 USD
CY2015Q4 nuro Stockholders Equity Note Reverse Stock Split Conversion Ratio
StockholdersEquityNoteReverseStockSplitConversionRatio
1-for-4
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h2 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: bold 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> </h2> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 24px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Use of Estimates and Assumptions</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left"></div> <h3 style="TEXT-ALIGN: left; PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 0pt; MARGIN: 0pt; PADDING-LEFT: 24px; PADDING-RIGHT: 0pt; FONT: bold italic 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 5pt"> Concentrations of Credit Risk</h3> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents in bank deposit accounts and trade receivables. The Company invests its funds in highly rated institutions and limits its investment in any individual account so that they do not exceed FDIC limits. The Company has not experienced significant losses related to cash and cash equivalents and does not believe it is exposed to any significant credit risks relating to its cash and cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">At December 31, 2016 and 2015, two customers accounted for 41% of accounts receivable and a different customer accounted for 46% of accounts receivable, respectively. For the year ended December 31, 2016 no customer accounted for more than 10% of revenue. For the years ended December 31, 2015 and 2014, one customer accounted for 12% and 30% of revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;PADDING-BOTTOM: 3pt; TEXT-TRANSFORM: none; TEXT-INDENT: 20px; MARGIN: 0pt; PADDING-LEFT: 4px; PADDING-RIGHT: 0pt; FONT: 10pt/12pt Times New Roman, Times, Serif; PADDING-TOP: 3pt" align="left">The Company relies on in-house assembly and three third-party manufacturers to manufacture the major portion of its current products and product components. The disruption or termination of the supply of these products or a significant increase in the cost of these products from these sources could have an adverse effect on the Company&#8217;s business, financial position, and results of operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6694901 shares
CY2016Q4 us-gaap Deferred Revenue And Credits Current
DeferredRevenueAndCreditsCurrent
1247545 USD
CY2016Q4 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
619309 USD
CY2015Q4 us-gaap Deferred Revenue And Credits Current
DeferredRevenueAndCreditsCurrent
489467 USD
CY2015Q4 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
262295 USD
CY2016Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
910595 USD
CY2015Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
378440 USD
CY2016Q4 nuro Accrued Sales Return Allowance Current
AccruedSalesReturnAllowanceCurrent
488200 USD
CY2015Q4 nuro Accrued Sales Return Allowance Current
AccruedSalesReturnAllowanceCurrent
65111 USD
CY2016 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
6311000 USD
CY2015 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2499000 USD
CY2014 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
481000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
530674 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
630361 USD
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
656647 USD
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
466906 USD
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
432437 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
154971 USD
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3100216 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2999717 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2567510 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2316183 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
542645 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
547018 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
475408 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
487379 USD
CY2016Q4 nuro Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
81562 USD
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2664686 USD
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
28538 USD
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4047332 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4047332 shares
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
7194975 USD
CY2016Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2270000 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016Q4 nuro Minimum Bid Price Per Share
MinimumBidPricePerShare
1.00

Files In Submission

Name View Source Status
0001144204-17-007088-index-headers.html Edgar Link pending
0001144204-17-007088-index.html Edgar Link pending
0001144204-17-007088.txt Edgar Link pending
0001144204-17-007088-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
line.gif Edgar Link pending
nuro-20161231.xml Edgar Link completed
nuro-20161231.xsd Edgar Link pending
nuro-20161231_cal.xml Edgar Link unprocessable
nuro-20161231_def.xml Edgar Link unprocessable
nuro-20161231_lab.xml Edgar Link unprocessable
nuro-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spacer.gif Edgar Link pending
v458118_10k.htm Edgar Link pending
v458118_ex10-17.htm Edgar Link pending
v458118_ex10x2x6.htm Edgar Link pending
v458118_ex4x2x9.htm Edgar Link pending
v458118_exh23x1.htm Edgar Link pending
v458118_exh31x1.htm Edgar Link pending
v458118_exh31x2.htm Edgar Link pending
v458118_exh32.htm Edgar Link pending